Cision PR Newswire

Runjian Co., Ltd. Showcases Token-as-a-Service and AI Innovations at AIMX Singapore 2026

SINGAPORE, Aug. 30, 2026 /PRNewswire/ -- AIMX Singapore 2026 has successfully concluded at Sands Expo & Convention Centre. Mr Tan Kiat How, Senior Minister of State, Ministry of Digital Development and Information, visited Runjian Co., Ltd.'s booth. As an official Platinum Partner of the event, Runjian focused firmly on...

Club Med Breaks Ground on Koh Samui: First Exclusive Collection Resort in Thailand

KOH SAMUI, Thailand, Aug. 29, 2026 /PRNewswire/ -- A groundbreaking ceremony for the new...

YFORE Debuts ODMS In-Cabin Sensing System to Enhance Cockpit Safety

SUWANEE, Ga., Aug. 29, 2026 /PRNewswire/ -- Marking the official opening of its North...

Niutech Signs Agreement with Global Energy Major for Waste Plastic Pyrolysis Line to Produce SAF

JINAN, China, Aug. 29, 2026 /PRNewswire/ -- Niutech Technology Group Co., Ltd (abbreviated as...

China Daily: ‘A Date with China•Meet Xinjiang’ intl media tour kicks off in Urumqi

URUMQI, China, Aug. 29, 2026 /PRNewswire/ -- The 2026 "A Date with China: Meet...

India’s Bharti Airtel partners Ericsson 5G Core technology to drive 5G evolution

New agreement spans packet core, signaling, charging & policy solutions STOCKHOLM, Feb. 25, 2025 /PRNewswire/ -- India's Bharti...

BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)

SHANGHAI, Feb. 23, 2025 /PRNewswire/ -- BioCity Biopharma (BioCity) announced that its selective endothelin receptor type A (ETA) antagonist, SC0062, met the 12-week primary endpoint...

How 51Talk is Redefining Online Education Through AI–from the Boardroom to the Classroom

SINGAPORE, Feb. 25, 2025 /PRNewswire/ -- 51Talk, an online English language education platform, has announced plans to launch a comprehensive, AI-powered systems upgrade across its...

Consensus concludes sold-out debut event in Hong Kong and announces return to Asia in 2026

The Hong Kong Convention and Exhibition Centre reached maximum capacity, with nearly 10,000 in-person attendees from over 100 countries, solidifying the...

CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA

Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The GEMSTONE-303...